Document:

Exhibit 10.4

 

FORM OF AMENDED AND RESTATED VOTING AGREEMENT

 

AMENDED AND RESTATED VOTING

AGREEMENT, dated as of December    , 2002, by and among Krupp

Government Income Trust, a Massachusetts business trust (“GIT”), Krupp

Government Income Trust II, a Massachusetts business trust (“GIT II” and,

collectively with GIT, the “TRUSTS”), and Berkshire Income Realty, Inc.

(“BIR”), a Maryland corporation.

 

WHEREAS, BIR intends to

commence exchange offers pursuant to which it will seek to acquire shares of

beneficial interest, no par value, of each of the Trusts (the “SHARES”) in

exchange for shares of BIR’s Series A Cumulative Redeemable Preferred Stock

(collectively, the “EXCHANGE OFFERS”);

 

WHEREAS, in order to address

concerns that might be raised by the holders of Shares, who decide not to

tender their Shares in the Exchange Offers, that BIR might use the voting power

of the Shares acquired by it in the Exchange Offers in a manner that may not be

consistent with the interests of such holders, the parties entered into the

Voting Agreement, dated as of November 1, 2002 (the “ORIGINAL AGREEMENT”); and

 

WHEREAS, the parties hereto

wish to amend and restate the Original Agreement in its entirety.

 

NOW, THEREFORE, in

consideration of the above recitals and the mutual covenants and agreements

made herein, the parties hereto agree as follows:

 

1. VOTING AGREEMENT. Subject

to Section 2 below, BIR hereby agrees, so long as it or any of its affiliates

has voting power with respect to any Shares (regardless of whether such Shares

have been acquired in the Exchange Offers or otherwise) (the “BIR SHARES”),

that, at any meeting of the holders of Shares of GIT or GIT II, however called,

or in connection with a written consent of the holders of Shares of GIT or GIT

II, BIR shall vote or consent (or cause to be voted or consented) with respect

to any matter brought before such holders of Shares, all of the BIR Shares in

proportion to the votes cast by the other holders of Shares of GIT and GIT II,

respectively.

 

2. EFFECTIVENESS. This

Agreement shall not be effective unless and until the Exchange Offers have been

completed and BIR has acquired Shares pursuant thereto (the “EFFECTIVE DATE”).

 

3. THIRD PARTY

BENEFICIARIES; TERMINATION. Each holder of Shares other than BIR or any

affiliate of BIR (each, an “UNAFFILIATED HOLDER”) is intended to be and is

expressly made a third party beneficiary of this Agreement, and each

Unaffiliated Holder is expressly permitted to enforce all of the provisions

hereunder as if each was a party hereto. This Agreement may not be terminated

by the parties after the Effective Date without the consent of the holders of a

majority of the Shares (exclusive of any Shares not held by Unaffiliated

Holders).

 

 

4. AMENDMENTS. From and

after the Effective Date, no amendment of Section 1 of this Agreement shall be

valid and binding unless the same shall be in writing and signed by (1) each of

the Trusts, whose execution may only be authorized with the approval of a

majority of the independent trustees of the Board of Trustees of each of the

Trusts, (2) the holders of a majority of the Shares (exclusive of any Shares

not held by Unaffiliated Holders), and (3) BIR.

 

5. ASSIGNMENT. This

Agreement may not be assigned by a party without the consent of the other

parties hereto. This Agreement shall be binding upon and inure to the benefit

of the parties hereto and their respective successors and permitted assigns.

 

6. ENTIRE AGREEMENT. This

Agreement constitutes the entire agreement among the parties hereto with

respect to the subject matter hereof, and supersedes any and all prior

discussions or agreements, whether written or oral, with respect thereto.

 

7. COUNTERPARTS. This

Agreement may be executed in any number of counterparts, each of which shall be

deemed an original, but all of which together shall constitute but one and the

same instrument.

 

8. HEADINGS. The headings

contained in this Agreement are for convenience purposes only and shall not in

any way affect the meaning or interpretation hereof.

 

9. GOVERNING LAW. This

Agreement shall be governed by and construed in accordance with the domestic

substantive laws of The Commonwealth of Massachusetts, without giving effect to

any choice or conflict of law provision or rule that would cause the

application of the laws of any other jurisdiction.

 

IN WITNESS WHEREOF, each of

the undersigned has executed this Agreement as of the date first above written.

 

 

	

   

  	

  KRUPP

  GOVERNMENT INCOME TRUST

  
	

   

  	

   

  	

   

  
	

   

  	

   

  	

   

  
	

   

  	

  By:

  	

   

  	

   

  
	

   

  	

   

  	

  Name:

  Douglas Krupp

  
	

   

  	

   

  	

  Title:

  Chairman

  
	

   

  	

   

  	

   

  
	

   

  	

   

  	

   

  
	

   

  	

  KRUPP

  GOVERNMENT INCOME TRUST II

  
	

   

  	

   

  	

   

  
	

   

  	

  By:

  	

   

  	

   

  
	

   

  	

   

  	

  Name:

  Douglas Krupp

  
	

   

  	

   

  	

  Title:

  Chairman

  
	

   

  	

   

  	

   

  
	

   

  	

  BERKSHIRE

  INCOME REALTY, INC.

  
	

   

  	

   

  	

   

  
	

   

  	

  By:

  	

   

  	

   

  
	

   

  	

   

  	

  Name:  David Quade

  
	

   

  	

   

  	

  Title:

  President

  
						

 

2Exhibit 10.5

 

Berkshire Income Realty, Inc.

One Beacon Street,

Suite 1500

Boston,

Massachusetts  02108

 

March 5, 2003

 

 

Krupp Government Income Trust

Krupp Government Income Trust

II

One Beacon Street

Boston, Massachusetts  02108

 

Gentlemen:

 

 

Reference is made to the Waiver

and Standstill Agreement, dated as of August 22, 2002, by and among Krupp

Government Income Trust (“GIT”), Krupp Government Income Trust II

(“GIT II” and, collectively with GIT, the “Trusts”),

Berkshire Income Realty, Inc. and Berkshire Income Realty-OP, L.P. (the “Waiver

Agreement”).

 

This is to confirm our

agreement that, notwithstanding the first sentence of Section 2.3 of the

Waiver Agreement, the expiration date of the exemption granted by the Trusts in

Section 2.1 of the Waiver Agreement is hereby extended from March 31,

2003 to June 30, 2003.  Except for

the foregoing, all of the terms and conditions of the Waiver Agreement remain

in full force and effect.

 

Kindly confirm the foregoing by

signing below.

 

 

	

  BERKSHIRE

  INCOME REALTY, INC.

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

  By:

  	

  /s/ David C.

  Quade

  	

   

  
	

   

  	

   

  	

  Name: David C. Quade

  	

   

  
	

   

  	

   

  	

  Title: President

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

   

  	

  BERKSHIRE

  INCOME REALTY-OP, L.P.

  	

   

  
	

   

  	

  by:

  	

  Berkshire

  Income Realty, Inc., its General Partner

  
	

   

  	

  By:

  	

  /s/ David C.

  Quade

  	

   

  
	

   

  	

   

  	

  Name: David C. Quade

  	

   

  
	

   

  	

   

  	

  Title: President

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

  Acknowledged

  and agreed as of the date first above written:

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

   

  	

  KRUPP

  GOVERNMENT INCOME TRUST

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

  By:

  	

  /s/ Douglas

  Krupp

  	

   

  
	

   

  	

   

  	

  Name: Douglas Krupp

  	

   

  
	

   

  	

   

  	

  Title: Chairman

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

   

  	

  KRUPP

  GOVERNMENT INCOME TRUST II

  	

   

  
	

   

  	

   

  	

   

  	

   

  
	

   

  	

  By:

  	

  /s/ Douglas

  Krupp

  	

   

  
	

   

  	

   

  	

  Name: Douglas Krupp

  	

   

  
	

   

  	

   

  	

  Title: ChairmanExhibit
10.25

 

[Portions of this Exhibit have been
omitted pursuant to a request for confidentiality under Rule 24b-2 of the
Securities Exchange Act of 1934, as amended. 
A copy of this Exhibit with all sections intact has been filed
separately with the Securities and Exchange Commission.]

 

 

Amendment No. 5

to the

License Agreement dated 13th of June 2000 (the

“Agreement”)

by and between

Antares Pharma IPL AG

Zug, Switzerland

as Licensor

(formerly known as Permatec Technologie AG)

and

BioSante Pharmaceuticals, Inc.

Lincolnshire, IL, U.S.A.

as Licensee

 

WHEREAS, Antares Pharma IPL AG, Zug,
Switzerland (“Antares”) and BioSante Pharmaceuticals, Inc., Lincolnshire,
Illinois (“BioSante”) have previously entered into a License Agreement dated
June 13, 2000 (“Agreement”), regarding the grant of a license with the right to
sublicense specified products, as well as a Supply Agreement of the same date;

 

WHEREAS, Antares and BioSante have also
entered into a series of four amendatory agreements subsequent to June 13,
2000, each of which has made specified amendments to the terms of the
Agreement, as follows: Amendment No. 1, dated May 20, 2001; Amendment No. 2,
dated July 5, 2001; Amendment No. 3, dated August 30, 2001; and Amendment No.
4, August 8, 2002;

 

WHEREAS, Antares and BioSante each
acknowledge that Antares and BioSante have identified issues involving
interpretation of the Agreement and the amendatory agreements regarding which
they disagree, specifically as to the appropriate timing of the milestone
payment provided for in paragraph 3.3.3 of the Agreement, as modified by
section 1-4(B) of Amendment No. 4, and the agreed geographical location of
product development activities; and

 

 

WHEREAS, Antares and BioSante each desire
to resolve their differences without acknowledging the accuracy or validity of
the assertions of the other, except as may be set forth herein, and desire to
continue their business relationship subject to some altered terms;

 

NOW THEREFORE, Antares and BioSante hereby
agree pursuant to this Amendment No. 5 to the License Agreement dated 13th
of June 2000 (“Amendment No. 5”) to amend the Agreement as follows:

 

A.            MILESTONE

 

In order to
perform its obligations under paragraph 3.3.3 of the Agreement, as modified by
paragraph 1-4(B) of Amendment No. 4, Antares and BioSante agree that BioSante
shall pay

 

(1)                                  the
sum of Two Hundred Thousand Dollars (USD 200,000), upon execution of this
Amendment No. 5; and

(2)                                  an
additional XXXXXXXXXXXXXXXXXX Dollars (XXXXXXXXXX) upon the start of a clinical
trial of E2-XXXX Combi Gel in the USA or upon filing of a New Drug Application
with the US Food and Drug Administration for E2-XXXX Combi Gel by Solvay
Pharmaceuticals, whichever occurs first.

 

[A portion of this section has been
omitted pursuant to a request for confidential treatment under Rule 24b-2 under
the Securities Exchange Act of 1934, as amended.  A copy of this section with the portion intact has been filed
separately with the Securities and Exchange Commission]

 

The Parties agree and
acknowledge that the above sums are in full and complete performance of the
obligations in paragraph 3.3.3 of the Agreement, as modified by paragraph
1-4(B) of Amendment No. 4, and in full and complete settlement and resolution
of their differences with respect to such paragraphs, and that payment of such
sums are in addition to and different than payment of any other sums provided
for in the Agreement and any of the four prior amendments to it.

 

B.            GEOGRAPHY OF DEVELOPMENT ACTIVITIES

 

In order to
resolve the Parties’ disagreement regarding the proper geographical location of
development activities for defined Products:

 

(1)                                  BioSante
hereby acknowledges and agrees that its license from Antares regarding E2-XXXX
Combi Gel includes marketing rights only in the United States and Canada, and
regarding other Products, only in countries specifically enumerated in the
Agreement and/or one or more of the amendments to it, and hereby reaffirms that
it has no intention of undertaking or sublicensing development activities for
any purposes other than achieving regulatory approval and making subsequent
sales and undertaking related support activities in the countries with respect
to which it has received such licenses from Antares; and

 

2

 

[A portion of this section has been
omitted pursuant to a request for confidential treatment under Rule 24b-2 under
the Securities Exchange Act of 1934, as amended.  A copy of this section with the portion intact has been filed
separately with the Securities and Exchange Commission]

 

(2)                                  Antares
and BioSante hereby acknowledge and agree that, under the terms of the
Agreement and the five amendments to it, activities constituting Development of
any Product may be undertaken in any geographical location inside or outside
the agreed and defined Territory for such Product, whether undertaken by
BioSante or its sublicensee Solvay Pharmaceuticals regarding E2-XXXX
Combi Gel, or any other sublicensee regarding any other Product, or any future
sublicensee, assignee or designee.  The
choices of location of such activities are in the sole discretion of BioSante,
Solvay or its assignee or designee, and such entities will not, by virtue of
their choice of location alone, be considered to be in breach of the Agreement
or any amendment to it.  As in section
B(1) above, it is acknowledged that all such activity will be directed toward
achieving regulatory approval and making subsequent sales and undertaking
related support activities in the territories in which BioSante, its current or
future sub licensees, or any future sub licensees, designees or assignees have
rights to the Products as specified in the Agreement and all amendments.

 

[A portion of this section has been
omitted pursuant to a request for confidential treatment under Rule 24b-2 under
the Securities Exchange Act of 1934, as amended.  A copy of this section with the portion intact has been filed
separately with the Securities and Exchange Commission]

 

C.            MISCELLANEOUS

 

The parties agree that
the Agreement shall, except for and in due incorporation of the amendments
agreed upon in Amendment No. 1, dated May 20, 2001; Amendment No. 2, dated July
5, 2001; Amendment No. 3, dated August 30, 2001; Amendment No. 4, dated August
8, 2002, and this Amendment No. 5, remain in full force and effect and is not
otherwise changed, altered or amended.

 

3

 

IN WITNESSETH WHEREOF,
the Parties have duly executed this Amendment effective as of the 30th day of
December, 2002.

 

	
  Antares Pharma IPL AG

  	
   

  	
   

  
	
  PA

  	
  12/30/02
  

  	
   

  	
  /s/ Roger G. Harrison 

  
	
  Place
  and Date

  	
   

  	
  By:   Roger G. Harrison 

  
	
   

  	
   

  	
  Its:    President and CEO

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  BioSante Pharmaceuticals, Inc.

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Lincolnshire, IL

  	
  12/27/02

  	
   

  	
  /s/ Stephen M. Simes 

  
	
  Place
  and Date

  	
   

  	
  By:   Stephen M. Simes 

  
	
   

  	
   

  	
  Its:    President and CEO

  

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]